Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension. 1980

M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers

The efficacy of labetalol, an alpha and beta adrenoceptor blocking drug, has been compared with that of placebo, of propranolol alone, of hydrallazine alone, and of hydrallazine plus propranolol in combination in a randomized double-blind, fixed-dose crossover trial. Labetalol (300 mg twice a day) was equally effective with propranolol (80 mg twice a day), and more effective than hydrallazine (50 mg twice a day) alone. The effect of labetalol was comparable with that of hydrallazine plus propranolol when the patient was standing, but less potent with the patient in the supine position. Side effects were few.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007741 Labetalol A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. AH-5158,Albetol,Apo-Labetalol,Dilevalol,Labetalol Hydrochloride,Labetalol, (R,R)-Isomer,Labetolol,Normodyne,Presolol,R,R-Labetalol,SCH-19927,Trandate,AH 5158,AH5158,Apo Labetalol,ApoLabetalol,Hydrochloride, Labetalol,R,R Labetalol,SCH 19927,SCH19927
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005260 Female Females

Related Publications

M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
March 1980, British journal of clinical pharmacology,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
January 1980, Postgraduate medical journal,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
August 1976, British journal of clinical pharmacology,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
February 1980, British journal of obstetrics and gynaecology,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
January 1979, British journal of clinical pharmacology,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
October 1957, Irish journal of medical science,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
January 1983, International journal of clinical pharmacology research,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
January 1986, Clinical therapeutics,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
January 1987, European journal of clinical pharmacology,
M J West, and L M Wing, and J Mulligan, and J Walkley, and J J Grygiel, and J R Graham, and J P Chalmers
January 1980, Indian heart journal,
Copied contents to your clipboard!